Contineum Therapeutics

Contineum Therapeutics

Contineum Therapeutics incorporated in 2020 and operates from San Diego, with Carmine Stengone serving as CEO. The firm did not emerge from a family fortune or a wealth-management lineage; it was purpose-built as a clinical-stage biotech company targeting diseases with high unmet need in neuroscience, inflammation, and immunology. The company's strategy centers on acquiring or in-licensing drug candidates that have already cleared early safety and proof-of-concept hurdles, then advancing them through mid- and late-stage clinical trials. Lead asset PIPE-791, a lysophosphatidic acid type 1 receptor antagonist licensed from a major pharmaceutical partner, entered Phase 2 for idiopathic pulmonary fibrosis and progressive multiple sclerosis. A second asset, PIPE-307 — an M1 receptor antagonist — targets relapsing-remitting multiple sclerosis. Contineum closed an initial public offering on the Nasdaq in April 2024, raising approximately $150 million in gross proceeds, with a stated deployment focus on North American and European clinical sites. Contineum is tightly structured around a small team of drug developers and business-development professionals. It does not operate adjacent venture funds, philanthropic foundations, or real-asset arms. The company scaled through a series of venture rounds led by Versant Ventures and Boxer Capital, then accelerated into the public markets. April 2024: Completed an upsized IPO on the Nasdaq under the ticker CTNM, raising gross proceeds of roughly $150 million to fund Phase 2 trials. Unlike platform biotechs that aim to spin out multiple separate drug companies, Contineum concentrates capital on advancing two internally held programs toward regulatory milestones. The model depends almost entirely on in-licensing and clinical execution rather than internal drug discovery, making the firm structurally closer to a specialized development-stage aggregator than to a traditional early-stage biotech.